Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：24
|
作者：
Koerkamp, B. Groot [1 ]
Janssen, Q. P. [1 ]
van Dam, J. L. [1 ]
Bonsing, B. A. [2 ]
Bos, H. [3 ]
Bosscha, K. P. [4 ]
Haberkorn, B. C. M. [5 ]
de Hingh, I. H. J. T. [6 ]
Karsten, T. M. [7 ]
Van der Kolk, M. B. [8 ]
Liem, M. S. L. [9 ]
Loosveld, O. J. L. [10 ]
Patijn, G. A. [11 ]
van Santvoort, H. C. M. [12 ]
de Vos-Geelen, J. [13 ]
van der Holt, B. [14 ]
Homs, M. Y. V. [15 ]
van Tienhoven, G. [16 ]
Besselink, M. G. [17 ]
Wilmink, H. W. [18 ]
机构：
[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands
[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands
[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands
[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands
[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands
[6] Catharina Hosp, Surg, Eindhoven, Netherlands
[7] OLVG Hosp, Surg, Amsterdam, Netherlands
[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands
[9] Med Spectrum Twente, Surg, Enschede, Netherlands
[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands
[11] Isala Hosp, Surg, Zwolle, Netherlands
[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands
[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands
[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands
[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands
[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands
[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands
[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA83
引用
收藏
页码：S1323 / S1323
页数：1
相关论文
共 50 条
  • [41] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (6) : 4121 - 4122
  • [42] Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer
    Tajima, Hidehiro
    Ohta, Tetsuo
    Okazaki, Mitsuyoshi
    Yamaguchi, Takahisa
    Ohbatake, Yoshinao
    Okamoto, Koichi
    Nakanuma, Shinichi
    Kinoshita, Jun
    Makino, Isamu
    Nakamura, Keishi
    Miyashita, Tomoharu
    Takamura, Hiroyuki
    Ninomiya, Itasu
    Fushida, Sachio
    Nakamura, Hiroyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 157 - 166
  • [43] Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
    Versteijne, Eva
    van Eijck, Casper H. J.
    Punt, Cornelis J. A.
    Suker, Mustafa
    Zwinderman, Aeilko H.
    Dohmen, Miriam A. C.
    Groothuis, Karin B. C.
    Busch, Oliver R. C.
    Besselink, Marc G. H.
    de Hingh, Ignace H. J. T.
    ten Tije, Albert J.
    Patijn, Gijs A.
    Bonsing, Bert A.
    de Vos-Geelen, Judith
    Klaase, Joost M.
    Festen, Sebastiaan
    Boerma, Djamila
    Erdmann, Joris I.
    Molenaar, I. Quintus
    van der Harst, Erwin
    van der Kolk, Marion B.
    Rasch, Coen R. N.
    van Tienhoven, Geertjan
    TRIALS, 2016, 17
  • [44] Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
    Murphy, Janet E.
    Wo, Jennifer Y.
    Ryan, David P.
    Jiang, Wenqing
    Yeap, Beow Y.
    Drapek, Lorraine C.
    Blaszkowsky, Lawrence S.
    Kwak, Eunice L.
    Allen, Jill N.
    Clark, Jeffrey W.
    Faris, Jason E.
    Zhu, Andrew X.
    Goyal, Lipika
    Lillemoe, Keith D.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Ferrone, Cristina R.
    Hong, Theodore S.
    JAMA ONCOLOGY, 2018, 4 (07) : 963 - 969
  • [45] Survival Outcomes of Patients With Borderline Resectable and Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Short-Course Chemoradiotherapy With Capecitabine-Based vs. Gemcitabine-Based Concurrent Chemotherapy
    Neibart, S. S.
    Mamidanna, S.
    Chundury, A.
    Sayan, M.
    Alexander, H. R.
    August, D.
    Berim, L. D.
    Boland, P. M.
    Grandhi, M. S.
    Gulhati, P.
    Hochster, H. S.
    Kennedy, T. J.
    Langan, R. C.
    Spencer, K.
    Jabbour, S. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E64 - E64
  • [46] Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer
    He, X.
    Zheng, Y.
    Wang, Jiabao
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 62 - 66
  • [47] Clinicopathologic findings of borderline resectable pancreatic cancer after neoadjuvant chemoradiotherapy
    Naito, Yoshiki
    Nakayama, Masamichi
    Ishikawa, Hiroto
    Takahashi, Kenjiro
    Hisaka, Toru
    Okuda, Koji
    Fukahori, Masaru
    Ishida, Yusuke
    Okabe, Yoshinobu
    Mihara, Yutaro
    Tanigawa, Masahiko
    Akiba, Jun
    Torimura, Takuji
    Yano, Hirohisa
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
    Cloyd, Jordan M.
    Heh, Victor
    Pawlik, Timothy M.
    Ejaz, Aslam
    Dillhoff, Mary
    Tsung, Allan
    Williams, Terence
    Abushahin, Laith
    Bridges, John F. P.
    Santry, Heena
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [49] Preoperative Gemcitabine-based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer Reply
    Takahashi, Hidenori
    Ishikawa, Osamu
    ANNALS OF SURGERY, 2015, 262 (06) : E103 - E104
  • [50] Effect of neoadjuvant chemoradiotherapy on prognosis in resectable and borderline resectable pancreatic cancer with venous involvement.
    Nagai, Minako
    Sho, Masayuki
    Akahori, Takahiro
    Nakagawa, Kenji
    Nakamura, Kota
    Takagi, Tadataka
    Tanaka, Toshihiro
    Nishiofuku, Hideyuki
    Kichikawa, Kimihiko
    Ikeda, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345